Tarnished HALO For Targacept/AstraZeneca Nicotinic Receptor Modulator
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Targacept and AstraZeneca halted further development of their neuronal nicotinic receptor modulator AZD3480 for cognitive dysfunction in schizophrenia after the drug failed to meet its primary endpoint in the Phase II HALO trial, but a final decision on the compound will wait for an ongoing trial in attention-deficit/hyperactivity disorder